Current Status for Anaplastic Lymphoma Kinase in Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 703-711, 2018.
Article
em Zh
| WPRIM
| ID: wpr-772376
Biblioteca responsável:
WPRO
ABSTRACT
The incidence of ALK gene rearrangement in non-small cell lung cancer (NSCLC) was about 3% to 5%. ALK gene inhibitors have made great breakthrough in recent years, significantly extending the survival period of patients with ALK(+) advanced NSCLC. But the majority of patients will be acquired drug resistance after treatment. This article has been explained separately from the ALK genetic background, the detection method, the treatment of the three generations of ALK inhibitors and the strategy after drug resistance. It is desire to have reference value and reference meaning for clinical work.
.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Farmacologia
/
Receptores Proteína Tirosina Quinases
/
Carcinoma Pulmonar de Células não Pequenas
/
Resistencia a Medicamentos Antineoplásicos
/
Usos Terapêuticos
/
Inibidores de Proteínas Quinases
/
Tratamento Farmacológico
/
Fusão Gênica
/
Quinase do Linfoma Anaplásico
/
Genética
Limite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2018
Tipo de documento:
Article